News

Based on recent communications with the FDA, Duska believes that the proposed single, prospective, placebo-controlled, and randomized trial in patients presenting to the emergency room with paroxysmal supraventricular

Following the FDA’s ‘safe to proceed’ letter for the 18F-ML-10 IND, NST will expand its neurovascular disorders and cancer clinical programs into the US. The first protocol already

The company has reported net sales of $2.02 billion, including sales from divested businesses of $19 million. Worldwide sales of the company’s CRM products for the second quarter

The company posted a net income of $207 million in the second quarter of 2008, an increase of 11% compared to $186 million in the second quarter of

The company posted net sales of $893.74 million in the first quarter of fiscal 2009, an increase of 6.1% compared to $842.61 million reported for the corresponding period

The company attributed the lower second quarter earnings to the acquisition of biotech group Organon BioSciences. The company posted net sales of $4.9 billion in the second quarter

Worldwide sales were $6.1 billion in the second quarter of 2008, a decrease of 1% from the second quarter of 2007. For the first six months of 2008,

The intent of the collaboration between the three parties is to jointly conduct further research to discover and develop compounds that target the hepatitis C virus (HCV). The

Depomed’s ProQuin XR is exclusively licensed to Rottapharm|Madaus for Europe and is a once-daily extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. Antonino